Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) EBIT (2020 - 2023)

Historic EBIT for Therapeutics (RAPT) over the last 4 years, with Q4 2023 value amounting to -$33.2 million.

  • Therapeutics' EBIT fell 3596.25% to -$33.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$127.1 million, marking a year-over-year decrease of 4809.95%. This contributed to the annual value of -$127.1 million for FY2023, which is 4809.95% down from last year.
  • As of Q4 2023, Therapeutics' EBIT stood at -$33.2 million, which was down 3596.25% from -$33.9 million recorded in Q3 2023.
  • Therapeutics' 5-year EBIT high stood at -$12.5 million for Q2 2020, and its period low was -$33.9 million during Q3 2023.
  • Over the past 4 years, Therapeutics' median EBIT value was -$18.7 million (recorded in 2021), while the average stood at -$21.0 million.
  • Per our database at Business Quant, Therapeutics' EBIT crashed by 1696.97% in 2022 and then plummeted by 5646.74% in 2023.
  • Quarter analysis of 4 years shows Therapeutics' EBIT stood at -$13.1 million in 2020, then tumbled by 37.82% to -$18.0 million in 2021, then tumbled by 35.47% to -$24.4 million in 2022, then tumbled by 35.96% to -$33.2 million in 2023.
  • Its last three reported values are -$33.2 million in Q4 2023, -$33.9 million for Q3 2023, and -$28.4 million during Q2 2023.